CN103012187B - 一种新型二乙酰氨乙酸乙二胺化合物及其药物组合物 - Google Patents
一种新型二乙酰氨乙酸乙二胺化合物及其药物组合物 Download PDFInfo
- Publication number
- CN103012187B CN103012187B CN201310008977.3A CN201310008977A CN103012187B CN 103012187 B CN103012187 B CN 103012187B CN 201310008977 A CN201310008977 A CN 201310008977A CN 103012187 B CN103012187 B CN 103012187B
- Authority
- CN
- China
- Prior art keywords
- ethyl enediamine
- compound
- diaceturate
- enediamine diaceturate
- injection
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- -1 diacetyl acetic acid quadrol compound Chemical class 0.000 title abstract 3
- 239000000890 drug combination Substances 0.000 title abstract 3
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims abstract description 72
- 150000001875 compounds Chemical class 0.000 claims abstract description 42
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims abstract description 36
- 235000017557 sodium bicarbonate Nutrition 0.000 claims abstract description 36
- 239000000203 mixture Substances 0.000 claims abstract description 13
- 229940012017 ethylenediamine Drugs 0.000 claims description 117
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 claims description 99
- 238000002347 injection Methods 0.000 claims description 72
- 239000007924 injection Substances 0.000 claims description 72
- 239000000843 powder Substances 0.000 claims description 49
- 239000007788 liquid Substances 0.000 claims description 48
- ZSBXGIUJOOQZMP-UHFFFAOYSA-N Isomatrine Natural products C1CCC2CN3C(=O)CCCC3C3C2N1CCC3 ZSBXGIUJOOQZMP-UHFFFAOYSA-N 0.000 claims description 44
- ZSBXGIUJOOQZMP-JLNYLFASSA-N Matrine Chemical compound C1CC[C@H]2CN3C(=O)CCC[C@@H]3[C@@H]3[C@H]2N1CCC3 ZSBXGIUJOOQZMP-JLNYLFASSA-N 0.000 claims description 44
- 229930014456 matrine Natural products 0.000 claims description 44
- 239000002253 acid Substances 0.000 claims description 40
- MEIRRNXMZYDVDW-MQQKCMAXSA-N (2E,4E)-2,4-hexadien-1-ol Chemical compound C\C=C\C=C\CO MEIRRNXMZYDVDW-MQQKCMAXSA-N 0.000 claims description 38
- 239000008194 pharmaceutical composition Substances 0.000 claims description 32
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 25
- 125000003916 ethylene diamine group Chemical group 0.000 claims description 18
- 239000008215 water for injection Substances 0.000 claims description 17
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 claims description 6
- 150000001298 alcohols Chemical class 0.000 claims description 2
- 238000001953 recrystallisation Methods 0.000 abstract description 2
- PVGHQBCTMALNFO-UHFFFAOYSA-N 2-acetyl-3-oxobutanoic acid Chemical compound CC(=O)C(C(C)=O)C(O)=O PVGHQBCTMALNFO-UHFFFAOYSA-N 0.000 abstract 4
- NSOXQYCFHDMMGV-UHFFFAOYSA-N Tetrakis(2-hydroxypropyl)ethylenediamine Chemical compound CC(O)CN(CC(C)O)CCN(CC(C)O)CC(C)O NSOXQYCFHDMMGV-UHFFFAOYSA-N 0.000 abstract 4
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 abstract 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 abstract 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 abstract 2
- 239000001630 malic acid Substances 0.000 abstract 2
- 235000011090 malic acid Nutrition 0.000 abstract 2
- 239000000600 sorbitol Substances 0.000 abstract 2
- 206010067484 Adverse reaction Diseases 0.000 abstract 1
- 230000006838 adverse reaction Effects 0.000 abstract 1
- 230000002439 hemostatic effect Effects 0.000 abstract 1
- 230000002195 synergetic effect Effects 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 39
- 208000032843 Hemorrhage Diseases 0.000 description 23
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 18
- 238000000034 method Methods 0.000 description 17
- 238000003756 stirring Methods 0.000 description 16
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 238000011049 filling Methods 0.000 description 8
- 239000003643 water by type Substances 0.000 description 8
- 239000000126 substance Substances 0.000 description 6
- GKNAKQZZLBLSLI-UHFFFAOYSA-N 2-acetamidoacetic acid;ethane-1,2-diamine Chemical compound NCCN.CC(=O)NCC(O)=O.CC(=O)NCC(O)=O GKNAKQZZLBLSLI-UHFFFAOYSA-N 0.000 description 5
- 208000034158 bleeding Diseases 0.000 description 5
- 230000000740 bleeding effect Effects 0.000 description 5
- 230000000025 haemostatic effect Effects 0.000 description 5
- 238000005261 decarburization Methods 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000007710 freezing Methods 0.000 description 4
- 230000008014 freezing Effects 0.000 description 4
- 230000023597 hemostasis Effects 0.000 description 4
- 238000000465 moulding Methods 0.000 description 4
- 230000001954 sterilising effect Effects 0.000 description 4
- 238000009777 vacuum freeze-drying Methods 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 3
- 206010038727 Respiratory tract haemorrhage Diseases 0.000 description 3
- 206010047700 Vomiting Diseases 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 238000002425 crystallisation Methods 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 208000014617 hemorrhoid Diseases 0.000 description 3
- 231100000862 numbness Toxicity 0.000 description 3
- 210000001635 urinary tract Anatomy 0.000 description 3
- 230000008673 vomiting Effects 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 238000005286 illumination Methods 0.000 description 2
- 230000001678 irradiating effect Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 102000004317 Lyases Human genes 0.000 description 1
- 108090000856 Lyases Proteins 0.000 description 1
- 102000013566 Plasminogen Human genes 0.000 description 1
- 108010051456 Plasminogen Proteins 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- GZCGUPFRVQAUEE-SLPGGIOYSA-N aldehydo-D-glucose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O GZCGUPFRVQAUEE-SLPGGIOYSA-N 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 229940012957 plasmin Drugs 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (9)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310008977.3A CN103012187B (zh) | 2013-01-10 | 2013-01-10 | 一种新型二乙酰氨乙酸乙二胺化合物及其药物组合物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310008977.3A CN103012187B (zh) | 2013-01-10 | 2013-01-10 | 一种新型二乙酰氨乙酸乙二胺化合物及其药物组合物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103012187A CN103012187A (zh) | 2013-04-03 |
CN103012187B true CN103012187B (zh) | 2014-08-20 |
Family
ID=47961352
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310008977.3A Expired - Fee Related CN103012187B (zh) | 2013-01-10 | 2013-01-10 | 一种新型二乙酰氨乙酸乙二胺化合物及其药物组合物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103012187B (zh) |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0636626A1 (en) * | 1993-07-20 | 1995-02-01 | Laboratoires Glaxo Sa | Pyrazolopyrimidine Derivatives |
CN1422615A (zh) * | 2002-12-03 | 2003-06-11 | 陈义忠 | 二乙酰氨乙酸乙二胺大容量注射液及其制备方法 |
CN1504186A (zh) * | 2002-12-03 | 2004-06-16 | 陈义忠 | 二乙酰氨乙酸乙二胺大容量注射液及其制备方法 |
CN1768780A (zh) * | 2004-11-04 | 2006-05-10 | 杨明 | 一种治疗溃疡性结肠炎的药物组合物及其制备方法和用途 |
CN102367229A (zh) * | 2011-08-19 | 2012-03-07 | 江西新先锋医药有限公司 | 一种二乙酰氨乙酸乙二胺化合物及其药物组合物 |
CN102488663A (zh) * | 2011-12-19 | 2012-06-13 | 王保明 | 一种二乙酰氨乙酸乙二胺药物组合物及其制备方法 |
CN102641457A (zh) * | 2012-04-27 | 2012-08-22 | 山东恩康药业有限公司 | 一种治疗球虫的兽药复方制剂及其制备方法与应用 |
-
2013
- 2013-01-10 CN CN201310008977.3A patent/CN103012187B/zh not_active Expired - Fee Related
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0636626A1 (en) * | 1993-07-20 | 1995-02-01 | Laboratoires Glaxo Sa | Pyrazolopyrimidine Derivatives |
CN1422615A (zh) * | 2002-12-03 | 2003-06-11 | 陈义忠 | 二乙酰氨乙酸乙二胺大容量注射液及其制备方法 |
CN1504186A (zh) * | 2002-12-03 | 2004-06-16 | 陈义忠 | 二乙酰氨乙酸乙二胺大容量注射液及其制备方法 |
CN1768780A (zh) * | 2004-11-04 | 2006-05-10 | 杨明 | 一种治疗溃疡性结肠炎的药物组合物及其制备方法和用途 |
CN102367229A (zh) * | 2011-08-19 | 2012-03-07 | 江西新先锋医药有限公司 | 一种二乙酰氨乙酸乙二胺化合物及其药物组合物 |
CN102488663A (zh) * | 2011-12-19 | 2012-06-13 | 王保明 | 一种二乙酰氨乙酸乙二胺药物组合物及其制备方法 |
CN102641457A (zh) * | 2012-04-27 | 2012-08-22 | 山东恩康药业有限公司 | 一种治疗球虫的兽药复方制剂及其制备方法与应用 |
Also Published As
Publication number | Publication date |
---|---|
CN103012187A (zh) | 2013-04-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2008112311A (ru) | Препаративная форма аргатробана | |
JP2006298774A (ja) | 経皮吸収型フリーラジカル抑制製剤 | |
CN103304471B (zh) | 一种甲磺酸罗哌卡因化合物、其制备方法及其药物组合物 | |
JP5177785B2 (ja) | 周術期患者用薬剤 | |
CN107412152A (zh) | 一种盐酸右美托咪定注射液组合物 | |
WO2012037834A1 (zh) | 一种5α-雄甾(烷)-3β,5,6β-三醇注射剂及其制备方法 | |
CN103012187B (zh) | 一种新型二乙酰氨乙酸乙二胺化合物及其药物组合物 | |
CN106667901A (zh) | 一种硫酸核糖霉素注射液及其制备方法 | |
CN101961312B (zh) | 一种注射用硫辛酸组合物 | |
CN103610693B (zh) | 一种肠外营养注射液组合物 | |
WO2007143895A1 (fr) | Solution supersaturée de chlorhydrate de gemcitabine et son procédé de préparation | |
CN102718693A (zh) | 一种卡络磺钠化合物及其组合物 | |
CN110772487B (zh) | 一种二乙酰氨乙酸乙二胺的冻干方法 | |
CN101756949A (zh) | 一种盐酸氨溴索与半胱氨酸的组合物及其制备方法 | |
WO2014080784A1 (ja) | 長期間安定なオランザピンの水性医薬製剤 | |
JP2008120798A (ja) | ヘパリン製剤 | |
CN101380294B (zh) | 一种治疗出血病的固体分散药物制备方法 | |
JP4578576B2 (ja) | ガチフロキサシン含有水性液剤 | |
JP5535900B2 (ja) | ガチフロキサシン含有水性液剤、その製造方法、および、該水性液剤の低温保存および凍結融解時の沈殿生成を抑制する方法 | |
CN103027890B (zh) | 供注射用的布洛芬药物组合物 | |
CN105496954A (zh) | 一种肌松药物罗库溴铵的注射液的制备方法 | |
JP2006001945A (ja) | ビタミンb1配合末梢静脈投与用総合輸液剤 | |
JP2008189626A (ja) | 経口用グリチルリチン可溶化製剤及びその製造方法 | |
CN103012192A (zh) | 一种新型乙酰谷酰胺化合物及其药物组合物 | |
JP5217276B2 (ja) | 注射用抗菌剤の製造方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20130403 Assignee: Hubei Kangqin Pharmaceutical Co.,Ltd. Assignor: Huang Mingfang Contract record no.: 2015420000084 Denomination of invention: Novel diacetyl acetic acid quadrol compound and drug combination thereof Granted publication date: 20140820 License type: Exclusive License Record date: 20150515 |
|
LICC | Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model | ||
EM01 | Change of recordation of patent licensing contract | ||
EM01 | Change of recordation of patent licensing contract |
Change date: 20200901 Contract record no.: 2015420000084 Assignee after: HUBEI KANGQIN PHARMACEUTICAL Co.,Ltd. Assignee before: Hubei Kangqin Pharmaceutical Co.,Ltd. |
|
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20140820 |